Geulah Livshits
Stock Analyst at Chardan Capital
(4.43)
# 493
Out of 5,182 analysts
264
Total ratings
49.81%
Success rate
21.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $27 → $30 | $13.81 | +117.31% | 20 | Apr 27, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 | $3.39 | +371.98% | 16 | Apr 10, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $210 → $240 | $128.81 | +86.32% | 9 | Mar 31, 2026 | |
| SNTI Senti Biosciences Holdings | Maintains: Buy | $13 → $11 | $0.95 | +1,057.89% | 12 | Mar 30, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 | $3.47 | +217.00% | 23 | Mar 27, 2026 | |
| SLDB Solid Biosciences | Maintains: Buy | $15 | $7.48 | +100.53% | 11 | Mar 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $6.29 | +90.78% | 18 | Mar 19, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $9.47 | +174.55% | 15 | Mar 19, 2026 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $8 | $0.70 | +1,045.80% | 15 | Mar 12, 2026 | |
| EDIT Editas Medicine | Maintains: Buy | $3.5 | $3.06 | +14.57% | 11 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $220 → $323 | $270.10 | +19.59% | 15 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $76 | $51.99 | +46.18% | 17 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 | $5.78 | +194.12% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $11.62 | +115.24% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.34 | +274.53% | 15 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $21 | $5.65 | +271.68% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $3.70 | +143.24% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.44 | +666.55% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.20 | +173.35% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $9.15 | +348.09% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.88 | +317.39% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $47.61 | +336.88% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.09 | +1,367.89% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.68 | +936.87% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.76 | +6.38% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $23.57 | -23.63% | 1 | Oct 27, 2020 |
Intellia Therapeutics
Apr 27, 2026
Maintains: Buy
Price Target: $27 → $30
Current: $13.81
Upside: +117.31%
Iovance Biotherapeutics
Apr 10, 2026
Maintains: Buy
Price Target: $16
Current: $3.39
Upside: +371.98%
Palvella Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $210 → $240
Current: $128.81
Upside: +86.32%
Senti Biosciences Holdings
Mar 30, 2026
Maintains: Buy
Price Target: $13 → $11
Current: $0.95
Upside: +1,057.89%
Rocket Pharmaceuticals
Mar 27, 2026
Maintains: Buy
Price Target: $11
Current: $3.47
Upside: +217.00%
Solid Biosciences
Mar 20, 2026
Maintains: Buy
Price Target: $15
Current: $7.48
Upside: +100.53%
Taysha Gene Therapies
Mar 19, 2026
Maintains: Buy
Price Target: $12
Current: $6.29
Upside: +90.78%
4D Molecular Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $26
Current: $9.47
Upside: +174.55%
Tenaya Therapeutics
Mar 12, 2026
Maintains: Buy
Price Target: $8
Current: $0.70
Upside: +1,045.80%
Editas Medicine
Mar 9, 2026
Maintains: Buy
Price Target: $3.5
Current: $3.06
Upside: +14.57%
Feb 18, 2026
Maintains: Buy
Price Target: $220 → $323
Current: $270.10
Upside: +19.59%
Feb 17, 2026
Maintains: Buy
Price Target: $74 → $76
Current: $51.99
Upside: +46.18%
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $5.78
Upside: +194.12%
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $11.62
Upside: +115.24%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.34
Upside: +274.53%
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $5.65
Upside: +271.68%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.70
Upside: +143.24%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.44
Upside: +666.55%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.20
Upside: +173.35%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $9.15
Upside: +348.09%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.88
Upside: +317.39%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $47.61
Upside: +336.88%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.09
Upside: +1,367.89%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.68
Upside: +936.87%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.76
Upside: +6.38%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $23.57
Upside: -23.63%